Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence.

J Transl Med · 2021 · PMC8609739 · PMID 34809665

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

A similar trend was seen in CD4 + T cells in patients treated with zanubrutinib and in CD8 + T cells treated with either BTKi however this did not reach statistical significance (Fig. 2 D, E).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.